Epizyme Inc.

(EPZM) Trade

By |

Profile

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.

Contact Information

Website: www.epizyme.com
Email: ir@epizyme.com
Main Phone: +1 617 229-5872
Address: 400 Technology Square
Address 2: 4th Floor
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02139

Issuer Information

Exchange: NGS
CEO: Robert B. Bazemore
Employees: 131
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 5.65 $ -0.29 (-4.88%)
Last Price 5.65 Change $ -0.29 Change % -4.88 Tick N/A
Bid N/A Bid Size 0.00 Ask 6.48 Ask Size 500.00
Open 6.00 High 6.15 Low 5.56 Prev Close 5.94
Last Trade Volume 733,319 52 Wk Hi 21.40 52 Wk Low 5.56
Market Cap 447.3 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 79,168,053.00 EPS (TTM) -1.96 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 14
Number of Buys 0 9
Number of Sells 0 5
Net Activity 0 201895
Last 10 Buys Shares
David M. Mott 1,000
Tai-Ching Peter Ho 1,000
Carl S. Goldfischer 1,000
Carl S. Goldfischer 1,000
Forest Baskett 1,000
David M. Mott 1,000
Ravi Viswanathan 1,000
M. James Barrett 1,000
Sandell D Scott 1,000
Patrick J. Kerins 1,000
Last 10 Sell Shares
Tai-Ching Peter Ho 1,000
Tai-Ching Peter Ho 1,000
Tai-Ching Peter Ho 1,000
Andrew E. Singer 1,000
Tai-Ching Peter Ho 1,000
Robert A. Copeland 1,000
Tai-Ching Peter Ho 1,000
Robert A. Copeland 1,000
Robert A. Copeland 1,000
Robert A. Copeland 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 27 27 27 27
Low Target Price Estimate 16 16 16 16
Mean Target Price Estimate 23.25 23.25 23.25 23.5
Standard Deviation 3.54 3.54 3.54 3.66
Date of Most Recent Estimate 06/04/18 05/18/18 05/18/18 06/11/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 8 8 7 8
Moderate Buy 0 0 1 1
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.22 1.22 1.28 1.25